Tumor Biology

, Volume 35, Issue 7, pp 6521–6529 | Cite as

Evaluation of thyroid cancer in Chinese females with breast cancer by vascular endothelial growth factor (VEGF), microvessel density, and contrast-enhanced ultrasound (CEUS)

  • Xi Wei
  • Ying Li
  • Sheng Zhang
  • Gao MingEmail author
Research Article


To evaluate thyroid cancer in Chinese females with breast cancer by VEGF, MVD, and contrast-enhanced ultrasound (CEUS), 34 of 2,278 female inpatients with breast diseases who underwent routine thyroid ultrasonography were pathologically proved as thyroid cancer and enrolled into two groups: a breast cancer group and a non-breast cancer group. CEUS was performed and enhancement patterns were classified. Time-intensity curve parameters were analyzed to correlate with MVD CD34 and VEGF expression. Fourteen (2.6 %) and 20 (1.1 %) patients in breast cancer and non-breast cancer group were pathologically diagnosed as thyroid cancer. Six (42.8 %) and 0(0 %) patients showed high enhancement CEUS patterns of thyroid cancer in these two groups, respectively. The arrival time of time-intense curve was shorter, and the mean and peak intensity were higher in thyroid cancer in breast cancer group. The mean MVD counts and VEGF expression were significantly higher in thyroid and breast carcinomas in breast cancer group (P < 0.01). We also found that the mean and peak intensity were significantly associated with MVD counts and VEGF expression (P < 0.01). CEUS is recommended in evaluating the microcirculation of thyroid cancer in women with breast cancer and has the significant relationship with MVD counts and VEGF expression.


Thyroid cancer Breast cancer Vascular endothelial growth factor (VEGF) Microvessel density Contrast-enhanced ultrasound (CEUS) Chinese females 



We thank Dr. Xiaojie Xin, Ling Sun, Hailing Wang, Yong Xu, Li Cao, and Hua Chen for material support for this study.

Source of support

This study was supported by the Tianjin Municipal Health Bureau of Science and Technology Funds (2012KZ068 and 2010KZ067).

Conflicts of interest



  1. 1.
    Wei X, Li Y, Zhu Y, Zhang S. Microvascular of breast lesions evaluated by contrast enhancement ultrasound imaging combined with pathologic basis of angiogenesis. Chin J Clinicians. 2011;5:120–4. article in Chinese.Google Scholar
  2. 2.
    Wei X, Li Y, Zhang S, Zhu Y, Fan Y. Experience in large-core needle biopsy in the diagnosis of 1431 breast lesions. Med Oncol. 2011;28:429–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Eden K, Mahon S, Helfand M. Screening high-risk populations for thyroid cancer. Med Pediatr Oncol. 2001;36:583–91.CrossRefPubMedGoogle Scholar
  4. 4.
    Hardefeldt PJ, Eslick GD, Edirimanne S. Benign thyroid disease is associated with breast cancer: a meta-analysis. Breast Cancer Res Treat. 2012;133:1169–77.CrossRefPubMedGoogle Scholar
  5. 5.
    Nio Y, Iguchi C, Itakura M, et al. High incidence of synchronous or metachronous breast cancer in patients with malignant and benign thyroid tumor or tumor-like disorders. Anticancer Res. 2009;29:1607–10.PubMedGoogle Scholar
  6. 6.
    de Gonzalez Berrington A, Curtis RE, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011;12:353–60.CrossRefGoogle Scholar
  7. 7.
    Houtzager S, Wijkstra H, de la Rosette JJ, Laguna MP. Evaluation of renal masses with contrast-enhanced ultrasound. Curr Urol Rep. 2013;14:116–23.CrossRefPubMedGoogle Scholar
  8. 8.
    Amarteifio E, Krix M, Wormsbecher S, et al. Dynamic contrast-enhanced ultrasound for assessment of therapy effects on skeletal muscle microcirculation in peripheral arterial disease: pilot study. Eur J Radiol. 2012;82:640–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Dănilă M, Sporea I, Sirli R, Popescu A, Sendroiu M, Martie A. The role of contrast enhanced ultrasound (CEUS) in the assessment of liver nodules in patients with cirrhosis. Med Ultrason. 2010;12:145–9.PubMedGoogle Scholar
  10. 10.
    Xia Y, Jiang YX, Dai Q, Xiao Y, Lv K, Wang L. Contrast-enhanced ultrasound of hepatocellular carcinoma: correlation of washout time and angiogenesis. Clin Hemorheol Microcirc. 2011;48:265–73.PubMedGoogle Scholar
  11. 11.
    Uller W, Jung EM, Hornung M, et al. Evaluation of the microvascularization of pathologic parathyroid glands in patients with primary hyperparathyroidism using conventional ultrasound and contrast-enhanced ultrasound. Clin Hemorheol Microcirc. 2011;48:95–103.PubMedGoogle Scholar
  12. 12.
    Lee SH, Lee SJ, Jin SM, et al. Relationships between lymph node metastasis and expression of CD31, D2-40, and vascular endothelial growth factors A and C in papillary thyroid cancer. Clin Exp Otorhinolaryngol. 2012;5:150–5.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L, Maia AL. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2 in medullary thyroid carcinoma. Thyroid. 2010;20:863–71.CrossRefPubMedGoogle Scholar
  14. 14.
    Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol. 2007;88:271–7.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Saponaro C, Malfettone A, Ranieri G, et al. VEGF, HIF-1α Expression and MVD as an angiogenic network in familial breast cancer. PLoS One. 2013;8:e53070.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Chalstrey LJ, Benjamin B. High incidence of breast cancer in thyroid cancer patients. Br J Cancer. 1966;20:670–5.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Vassilopoulou-Sellin R, Palmer L, Taylor S, Cooksley CS. Incidence of breast carcinoma in women with thyroid carcinoma. Cancer. 1999;85:696–705.CrossRefPubMedGoogle Scholar
  18. 18.
    Chen AY, Levy L, Goepfert H, Brown BW, Spitz MR. Vassilopoulou-Sellin R. The development of breast carcinoma in women with thyroid carcinoma. Cancer. 2001;92:225–31.CrossRefPubMedGoogle Scholar
  19. 19.
    Park JS, Oh KK, Kim EK, Chang HS, Hong SW. Sonographic screening for thyroid cancer in females undergoing breast sonography. AJR Am J Roentgenol. 2006;186:1025–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Park JS, Oh KK, Kim EK, et al. Sonographic detection of thyroid cancer in breast cancer patients. Yonsei Med J. 2007;48:63–8.PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Smyth PP. The thyroid, iodine and breast cancer. Breast Cancer Res. 2003;5:235–8.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Cenqiz O, Bozkurt B, Unal B, et al. The relationship between prognostic factors of breast cancer and thyroid disorders in Turkish women. J Surg Oncol. 2004;87:19–25.CrossRefGoogle Scholar
  23. 23.
    Grani G, Dicorato P, Dainelli M, et al. Thyroid diseases in women with breast cancer. Clin Ter. 2012;163:e401–4.PubMedGoogle Scholar
  24. 24.
    Bartolotta TV, Midiri M, Galia M, et al. Qualitative and quantitative evaluation of solitary thyroid nodules with contrast-enhanced ultrasound: initial results. Eur Radiol. 2006;16:2234–41.CrossRefPubMedGoogle Scholar
  25. 25.
    Zhang B, Jiang YX, Liu JB, et al. Utility of contrast-enhanced ultrasound for evaluation of thyroid nodules. Thyroid. 2010;20:51–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Nemec U, Nemec SF, Novotny C, Weber M, Czerny C, Krestan CR. Quantitative evaluation of contrast-enhanced ultrasound after intravenous administration of a microbubble contrast agent for differentiation of benign and malignant thyroid nodules: assessment of diagnostic accuracy. Eur Radiol. 2012;22:1357–65.CrossRefPubMedGoogle Scholar
  27. 27.
    Huang SM, Lee JC, Wu TJ, Chow NH. Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J Surg. 2001;25:302–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol. 2000;66:475–80.CrossRefGoogle Scholar
  29. 29.
    Karpanen T, Egeblad M, Karkkainen MJ, et al. Vascular endo-thelial growth factor C promotes tumor lymphjangiogenesis and intralymphatic tumor growth. Cancer Res. 2001;61:1786–90.PubMedGoogle Scholar
  30. 30.
    Lewy-Trenda I, Wierzchniewska-Lawska A. Expression of vascular endothelial growth factor (VEGF) in human thyroid tumor. Pol J Pathol. 2002;53:129–32.PubMedGoogle Scholar
  31. 31.
    Fenton C, Patel A, Dinauer C, Robie DK, Tuttle RM, Francis GL. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid. 2000;10:349–57.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Diagnostic and Therapeutic UltrasonographyTianjin Medical University Cancer Institute and Hospital, Key laboratory of Cancer Prevention and TherapyTianjinChina
  2. 2.The Third Department of Breast CancerTianjin Medical University Cancer Institute and Hospital, Key laboratory of Cancer Prevention and TherapyTianjinChina
  3. 3.Department of Thyroid and Neck TumorTianjin Medical University Cancer Institute and Hospital, Key laboratory of Cancer Prevention and TherapyTianjinChina

Personalised recommendations